TRIB

BEARISH

$0.74 Live

Trinity Biotech plc · NASDAQ

$0.5 52W Range $3.44

TRIB Trinity Biotech plc - Fundamental Analysis

BEARISH

Console Chart News

TRIB Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$0.74

52W High

$3.44

52W Low

$0.5

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026

Market cap

$13.95M

P/E

N/A

ROE

N/A

Profit margin

-75.9%

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

90%

TRIB exhibits significant financial distress, characterized by a Piotroski F-Score of 4/9 (Stable) which masks deeper systemic issues. The most critical red flag is a negative Price-to-Book ratio (-0.25), indicating negative shareholders' equity. Despite a low Price-to-Sales ratio, the company suffers from negative profit margins (-75.88%) and a catastrophic 5-year price decline of 95.8%. Liquidity is precarious with a Quick Ratio of 0.47, suggesting an inability to meet short-term obligations without inventory liquidation.

Key Strengths

Low Price-to-Sales ratio (0.29) suggests the market is pricing the company well below its revenue

Positive Gross Margin (36.78%) indicates the core product has value before overhead

Recent short-term price recovery (+15.6% over 1 month)

Recent quarterly earnings beats (3 of last 4 quarters)

Positive most recent Q/Q EPS growth (+45.5%)

Key Risks

Negative Shareholders' Equity (P/B of -0.25) indicates insolvency risk

Severe negative profit margins (-75.88%)

Negative year-over-year revenue growth (-5.50%)

Poor liquidity position with a Quick Ratio of 0.47

Extreme long-term value destruction (-95.8% 5-year return)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Speculative

Key drivers: Negative Equity, Revenue Decline, Poor Liquidity, Long-term Price Collapse

Confidence

95%

Value

30/100

P/S is 0.29, but negative equity makes traditional valuation metrics like Graham Number inapplicable.

Positives

Very low P/S ratio

Watchpoints

Negative P/B ratio
No positive earnings for P/E calculation

Future

25/100

Revenue growth is -5.50%, contradicting the requirements for a growth-based recovery.

Positives

Recent EPS growth improvement

Watchpoints

Negative YoY revenue growth
Negative forward P/E

Past

10/100

Long-term trend is overwhelmingly bearish.

Positives

Recent 1-year bounce (+32.1%)

Watchpoints

5-year change of -95.8%
Consistent earnings volatility

Health

35/100

Piotroski score is the only metric preventing a total health failure, but negative equity is a critical red flag.

Positives

Piotroski F-Score of 4/9 is marginally stable

Watchpoints

Quick Ratio 0.47
Negative ROA (-9.46%)
Negative Equity

Dividend

0/100

Company is not in a position to return capital.

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$0.74

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TRIB and closest competitors.

Updated 2026-04-20

Company	5Y	3Y	1Y	6M	1M	1W
TRIB Trinity Biotech plc Primary	-95.8%	-86.8%	+32.1%	-28.2%	+15.6%	+5.7%
IVF INVO Fertility, Inc. Peer	-100.0%	-100.0%	-99.0%	-93.2%	-53.3%	-19.9%
HKPD Cellyan Biotechnology Co., Ltd Peer	-77.9%	-77.9%	-40.8%	-47.7%	-1.0%	+9.3%
MBAI Check-Cap Ltd. Peer	-94.0%	+34.3%	+175.7%	-5.8%	+4.0%	+5.3%
ICU SeaStar Medical Holding Corporation Peer	-99.8%	-99.3%	-70.8%	-35.1%	+33.9%	-13.9%

TRI

Trinity Biotech plc

Primary

-95.8%

-86.8%

+32.1%

-28.2%

+15.6%

+5.7%

IVF

INVO Fertility, Inc.

Peer

-100.0%

-99.0%

-93.2%

-53.3%

-19.9%

HKP

Cellyan Biotechnology Co., Ltd

Peer

-77.9%

-40.8%

-47.7%

-1.0%

+9.3%

MBA

Check-Cap Ltd.

Peer

-94.0%

+34.3%

+175.7%

-5.8%

+4.0%

+5.3%

ICU

SeaStar Medical Holding Corporation

Peer

-99.8%

-99.3%

-70.8%

-35.1%

+33.9%

-13.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-0.72

0.3

-0.25

0.29

8.05

-27.89

$13.95M

Profitability

Profit margins and return metrics

Profit Margin -75.88%

Operating Margin -3.56%

Gross Margin 36.78%

ROE N/A

ROA -9.46%

Growth

Revenue and earnings growth rates

Revenue Growth -5.5%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

1.03

Good

Quick Ratio

0.47

Poor

Cash/Share

$0.0

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2024

Revenue

$0.0B

Gross Margin

30.8%

Op. Margin

-54.0%

Net Margin

-106.9%

Total Assets

$0.1B

Liabilities

$0.1B

Equity

$-0.0B

Debt/Equity

-3.94x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

18%

Quarterly Earnings History

EPS performance vs analyst estimates

2025-07-01

$-0.48

+15.8% surprise

2025-05-15

$-0.88

-192.8% surprise

2024-11-15

$-0.43

+21.1% surprise

2024-08-14

$-0.47

+28.2% surprise

Healthcare Sector Comparison

Comparing TRIB against 498 companies in the Healthcare sector (28 bullish, 153 neutral, 317 bearish)

Profit Margin

-75.88%

This Stock

-15.87%

Sector Avg

+378.2% (Superior)

Revenue Growth

-5.5%

This Stock

137.48%

Sector Avg

-104.0% (Slower)

Current Ratio

1.03

This Stock

4.66

Sector Avg

-77.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
TRIB Trinity Biotech plc	BEARISH	$13.95M	-	-%	-75.9%	$0.74
IVF INVO Fertility, Inc.	BEARISH	$13.99M	-	-%	-%	$2.01	Compare
HKPD Cellyan Biotechnology Co., Ltd	BEARISH	$14.62M	-	-13.4%	-4.3%	$0.62	Compare
MBAI Check-Cap Ltd.	BEARISH	$13.12M	-	-130.1%	-%	$1.8	Compare
ICU SeaStar Medical Holding Corporation	BEARISH	$14.82M	-	-295.2%	-%	$3.71	Compare

TRIB Trinity Biotech plc

BEARISH

Mkt Cap

$14M

P/E

ROE

Price

$0.74

IVF INVO Fertility, Inc.

Compare with TRIB

Compare with TRIB

Compare with TRIB

Compare with TRIB

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F

2025-05-16

TRIB filed its annual report on Form 20-F on May 16, 2025. Due to the absence of provided excerpts, specific financial highlights and risk factors are unavailable for summary.

20-F

2024-04-30

TRIB filed its 20-F annual report on April 30, 2024, as a foreign private issuer. Specific financial highlights and risk factors were not provided in the available metadata for detailed analysis.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning TRIB from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

TRIB

TRIB Trinity Biotech plc - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

SEC Filings

Past News Coverage

Wait — Don't Miss Out!